HK1168005A1 - Methods for preventing and or treating degenerative disorders of the central nervous system - Google Patents

Methods for preventing and or treating degenerative disorders of the central nervous system

Info

Publication number
HK1168005A1
HK1168005A1 HK12108930.2A HK12108930A HK1168005A1 HK 1168005 A1 HK1168005 A1 HK 1168005A1 HK 12108930 A HK12108930 A HK 12108930A HK 1168005 A1 HK1168005 A1 HK 1168005A1
Authority
HK
Hong Kong
Prior art keywords
preventing
methods
nervous system
central nervous
degenerative disorders
Prior art date
Application number
HK12108930.2A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Boyd
Gary Lee
Original Assignee
阿米庫斯治療學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿米庫斯治療學公司 filed Critical 阿米庫斯治療學公司
Publication of HK1168005A1 publication Critical patent/HK1168005A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12108930.2A 2009-04-09 2012-09-12 Methods for preventing and or treating degenerative disorders of the central nervous system HK1168005A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
PCT/US2010/030470 WO2010118282A1 (fr) 2009-04-09 2010-04-09 Méthodes pour prévenir et/ou traiter des troubles dégénératifs du système nerveux central

Publications (1)

Publication Number Publication Date
HK1168005A1 true HK1168005A1 (en) 2012-12-21

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12108930.2A HK1168005A1 (en) 2009-04-09 2012-09-12 Methods for preventing and or treating degenerative disorders of the central nervous system

Country Status (12)

Country Link
US (1) US8304429B2 (fr)
EP (1) EP2416655B1 (fr)
JP (1) JP5634498B2 (fr)
CN (1) CN102448306B (fr)
AU (1) AU2010233187B2 (fr)
BR (1) BRPI1015472A2 (fr)
CA (1) CA2758187C (fr)
ES (1) ES2505243T3 (fr)
HK (1) HK1168005A1 (fr)
IL (1) IL215584A (fr)
NZ (1) NZ595630A (fr)
WO (1) WO2010118282A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010233188B2 (en) * 2009-04-09 2015-07-16 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
HUE041971T2 (hu) 2009-10-19 2019-06-28 Amicus Therapeutics Inc Új készítmények lizoszomális tárolási rendellenességek kezelésére és/vagy megelõzésére
CN102655747A (zh) * 2009-10-19 2012-09-05 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
JP6126009B2 (ja) 2010-11-17 2017-05-10 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． α−シヌクレイン発現の調節
WO2013070981A2 (fr) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Traitement de troubles associés à un stress du re en stabilisant l'homéostasie calcique intracellulaire
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
US10300077B2 (en) * 2016-09-12 2019-05-28 Steven Hoffman Compositions and methods for treating dementia
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
CA3088112A1 (fr) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Oligonucleotides antisens ciblant l'alpha-synucleine et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749423B1 (fr) * 1994-03-09 2003-06-18 Novo Nordisk A/S Piperidines et pyrrolidines
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
EP1558245A2 (fr) * 2002-10-28 2005-08-03 Novo Nordisk A/S Utilisation d'inhibiteurs de la glycogene phosphorylase pour le traitement de maladies cardio-vasculaires
CA2611011C (fr) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Traitement de troubles du snc associes a des mutations dans des genes codant pour des enzymes lysosomales
US7829579B2 (en) * 2006-06-23 2010-11-09 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
AU2010233188B2 (en) * 2009-04-09 2015-07-16 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders

Also Published As

Publication number Publication date
NZ595630A (en) 2013-04-26
US8304429B2 (en) 2012-11-06
CN102448306A (zh) 2012-05-09
ES2505243T3 (es) 2014-10-09
JP5634498B2 (ja) 2014-12-03
EP2416655A1 (fr) 2012-02-15
JP2012523430A (ja) 2012-10-04
EP2416655B1 (fr) 2014-06-25
CA2758187C (fr) 2017-03-07
CA2758187A1 (fr) 2010-10-14
WO2010118282A1 (fr) 2010-10-14
BRPI1015472A2 (pt) 2015-11-24
CN102448306B (zh) 2014-07-02
EP2416655A4 (fr) 2012-09-05
AU2010233187B2 (en) 2015-10-08
IL215584A (en) 2016-11-30
AU2010233187A1 (en) 2011-11-03
US20100261753A1 (en) 2010-10-14
IL215584A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
HK1168005A1 (en) Methods for preventing and or treating degenerative disorders of the central nervous system
HRP20170236T1 (hr) Novi pripravci za sprječavanje i/ili liječenje degenerativnih poremećaja središnjeg živčanog sustava
EP2485797A4 (fr) Dispositifs, systèmes et procédés pour le traitement de troubles et de d'affections neurologiques
EP2379559A4 (fr) Composés pyrimido-diazépinone d'échafaudage de kinase et procédés de traitement de troubles
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
SI2430022T1 (sl) 1,2,3-triazolo(4,3-a)piridin derivati in njihova uporaba za zdravljenje ali prepreäśevanje nevroloĺ kih in psihiatriäśnih nepravilnosti
EP2552433A4 (fr) Compositions et procédés pour le traitement de troubles somatosensoriels
IL213526A0 (en) Methods for treating acute myocardial infarctions and associated disorders
EP2170309A4 (fr) Procédés et compositions pour le traitement de troubles
EP2331088A4 (fr) Compositions et procédés de traitement de troubles psychiatriques
IL204785A0 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
GB2467710B (en) Methods for treating social disorders
GB2495885B (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
EP2550361A4 (fr) Compositions et procédés pour traiter des troubles neurologiques
HK1199831A1 (en) Composition for improving and or treating central nervous system degenerative disease
EP2672996A4 (fr) Méthodes et systèmes de traitement ou de prévention de troubles de l'hypertension associée à une grossesse
EP2618826A4 (fr) Composés de phénylpipéridine pour le traitement de troubles neurologiques et psychiatriques
HK1205503A1 (en) Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system //
EP2612668A4 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de troubles cérébraux neurologiques dégénératifs
EP2582832A4 (fr) Méthodes et compositions pharmaceutiques pour traitement du système nerveux central animal pour troubles psychiatriques
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2190981A4 (fr) Compositions cellulaires et procédé pour traiter les affections du système nerveux
EP2578206A4 (fr) Composition pharmaceutique pour traiter les affections de la partie inférieure du système urogénital
GB201219696D0 (en) Agents for the prevention and/or treatment of central nervous system damamge
AU2009902409A0 (en) Method for the treatment of mental disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220407